Introduction: Bacteria can deteriorate spermatozoal quality during semen cryopreservation, compromising artificial insemination (AI) success. Antibiotics are included in extenders to reduce the harmful effects of bacterial contamination. To the best of our knowledge, this is the first study to evaluate antibiotics in ring-necked pheasant semen cryopreservation.
Objectives: This study was designed to assess the efficiency of antibiotics (gentamicin, streptomycin, penicillin) on sperm quality and total aerobic bacterial count (TABC) of cryopreserved ring-necked pheasant (Phasianus colchicus) semen.
Methods: Semen from eight males (40 ejaculates) was pooled, diluted with Red Fowl Extender, and divided into five treatments including a control; experiments were repeated five times. Samples were cryopreserved using 10% glycerol and stored at -196°C. Sperm quality was assessed at multiple stages postdilution, postcooling, postequilibration, and post-thaw, along with fertility outcomes via AI. TABC was determined by culturing thawed samples at 37°C.
Results: All antibiotic treatments significantly improved semen quality compared with the control, with the streptomycin-penicillin (SP) combination yielding the best results across all stages. The SP group exhibited higher acrosome integrity and sperm livability (p < 0.01). Fertility trials showed higher fertilization and hatch rates in the postdilution group compared with the post-thaw group. TABC was below the detectable limits (<1.0 × 104 colony-forming units [CFU]/mL) in all the antibiotic-treated extenders compared with 1.1 × 104 CFU/mL in the control.
Conclusion: This study supports the use of antibiotic-enriched extenders to reduce bacterial contamination and enhance reproductive outcomes in avian AI programs, with potential benefits for conservation. Further work is recommended to elucidate mechanisms and optimize antibiotic concentration for long-term storage.
{"title":"Enhancing Fertility Potential of Cryopreserved Ring-Necked Pheasant Semen Through Antibiotic-Mediated Control of Bacterial Contamination.","authors":"Aasma Iqbal, Bushra Allah Rakha, Umer Ali, Shamim Akhter, Iffat Nayila","doi":"10.1177/19475535261428831","DOIUrl":"https://doi.org/10.1177/19475535261428831","url":null,"abstract":"<p><strong>Introduction: </strong>Bacteria can deteriorate spermatozoal quality during semen cryopreservation, compromising artificial insemination (AI) success. Antibiotics are included in extenders to reduce the harmful effects of bacterial contamination. To the best of our knowledge, this is the first study to evaluate antibiotics in ring-necked pheasant semen cryopreservation.</p><p><strong>Objectives: </strong>This study was designed to assess the efficiency of antibiotics (gentamicin, streptomycin, penicillin) on sperm quality and total aerobic bacterial count (TABC) of cryopreserved ring-necked pheasant (<i>Phasianus colchicus</i>) semen.</p><p><strong>Methods: </strong>Semen from eight males (40 ejaculates) was pooled, diluted with Red Fowl Extender, and divided into five treatments including a control; experiments were repeated five times. Samples were cryopreserved using 10% glycerol and stored at -196°C. Sperm quality was assessed at multiple stages postdilution, postcooling, postequilibration, and post-thaw, along with fertility outcomes via AI. TABC was determined by culturing thawed samples at 37°C.</p><p><strong>Results: </strong>All antibiotic treatments significantly improved semen quality compared with the control, with the streptomycin-penicillin (SP) combination yielding the best results across all stages. The SP group exhibited higher acrosome integrity and sperm livability (<i>p</i> < 0.01). Fertility trials showed higher fertilization and hatch rates in the postdilution group compared with the post-thaw group. TABC was below the detectable limits (<1.0 × 10<sup>4</sup> colony-forming units [CFU]/mL) in all the antibiotic-treated extenders compared with 1.1 × 10<sup>4</sup> CFU/mL in the control.</p><p><strong>Conclusion: </strong>This study supports the use of antibiotic-enriched extenders to reduce bacterial contamination and enhance reproductive outcomes in avian AI programs, with potential benefits for conservation. Further work is recommended to elucidate mechanisms and optimize antibiotic concentration for long-term storage.</p>","PeriodicalId":55358,"journal":{"name":"Biopreservation and Biobanking","volume":" ","pages":"19475535261428831"},"PeriodicalIF":1.4,"publicationDate":"2026-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147461011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-10DOI: 10.1177/19475535261429759
Maushumi Bhattacharjee, Julie Bérubé, Madeleine Durand, Simon Rousseau, Ma'n H Zawati
The COVID-19 pandemic underscored the urgent need for strong biobanking infrastructures to facilitate rapid research and innovation in public health emergencies. The COVID-19 Québec Biobank (BQC19), launched in March 2020, serves as a pioneering initiative to address this demand, enabling the collection, storage, and sharing of biological samples and data to advance diagnostics, therapeutics, and epidemiological research. This article examines the development and operational framework of BQC19, highlighting five key themes central to its success. First, BQC19's anticipatory governance model emphasizes adaptability, leveraging strategic foresight to maintain ethical and efficient operations during the pandemic. Second, the initiative's harmonized yet flexible consent processes ensured participant autonomy and compliance with evolving clinical and public health contexts. Third, BQC19's collaborative governance framework facilitated seamless interinstitutional cooperation, supported by standardized operating procedures and localized manuals of procedures. Fourth, streamlined data access mechanisms, managed by an independent data access committee, promoted ethical and equitable data sharing, balancing privacy considerations with research accessibility. Last, BQC19 demonstrates the transferability of its infrastructure to other health challenges, providing a scalable, ethical, and collaborative model for future public health crises. Through centralized data management, preestablished legal agreements, and tiered access protocols, BQC19 has significantly reduced response times and operational inefficiencies. Its achievements showcase the potential of biobanks in fostering global health collaboration, enabling rapid research mobilization, and addressing emerging health threats. BQC19's legacy lies in its ability to integrate innovation, ethics, and collaboration into a sustainable framework for public health preparedness.
{"title":"The Biobanque Québécoise de la COVID-19: Anticipate to Innovate.","authors":"Maushumi Bhattacharjee, Julie Bérubé, Madeleine Durand, Simon Rousseau, Ma'n H Zawati","doi":"10.1177/19475535261429759","DOIUrl":"https://doi.org/10.1177/19475535261429759","url":null,"abstract":"<p><p>The COVID-19 pandemic underscored the urgent need for strong biobanking infrastructures to facilitate rapid research and innovation in public health emergencies. The COVID-19 Québec Biobank (BQC19), launched in March 2020, serves as a pioneering initiative to address this demand, enabling the collection, storage, and sharing of biological samples and data to advance diagnostics, therapeutics, and epidemiological research. This article examines the development and operational framework of BQC19, highlighting five key themes central to its success. First, BQC19's anticipatory governance model emphasizes adaptability, leveraging strategic foresight to maintain ethical and efficient operations during the pandemic. Second, the initiative's harmonized yet flexible consent processes ensured participant autonomy and compliance with evolving clinical and public health contexts. Third, BQC19's collaborative governance framework facilitated seamless interinstitutional cooperation, supported by standardized operating procedures and localized manuals of procedures. Fourth, streamlined data access mechanisms, managed by an independent data access committee, promoted ethical and equitable data sharing, balancing privacy considerations with research accessibility. Last, BQC19 demonstrates the transferability of its infrastructure to other health challenges, providing a scalable, ethical, and collaborative model for future public health crises. Through centralized data management, preestablished legal agreements, and tiered access protocols, BQC19 has significantly reduced response times and operational inefficiencies. Its achievements showcase the potential of biobanks in fostering global health collaboration, enabling rapid research mobilization, and addressing emerging health threats. BQC19's legacy lies in its ability to integrate innovation, ethics, and collaboration into a sustainable framework for public health preparedness.</p>","PeriodicalId":55358,"journal":{"name":"Biopreservation and Biobanking","volume":" ","pages":"19475535261429759"},"PeriodicalIF":1.4,"publicationDate":"2026-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147391774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Introduction: The Biological Sample Management Platform (PGEB) of the Centre Léon Bérard is responsible for the preparation, preservation, storage, and provision of the institution's sample collection. The PGEB was approached to integrate a neuroblastoma collection, one of the most common pediatric cancers. This collection was initiated through the diagnostic reference activity for neuroblastoma at the Centre Léon Bérard.
Objectives: To requalify pediatric biological samples collected between 1984 and 2024 and to make them available for pediatric research protocols.
Methods: This study began with an assessment of the data associated with each of the 21,389 samples in the collection. These data were then compared with relevant regulations and consensus documents related to biobank data management, as well as the minimum data requirements for research use. Based on this, a methodology for sorting samples-either for retention or disposal-was applied.
Results: A set of minimum information criteria was established to revalue the samples. Various texts applicable in France mention the minimum data required for making samples available, but no consensus exists, either nationally or internationally. Furthermore, 65% of the samples met the criteria and were retained for future research use.
Conclusions: This article describes the research work that led to the identification of minimum required data. However, further development is needed to harmonize practices regarding data management and interoperability.
{"title":"Requalification and Data Management of Pediatric Biological Samples Collected since 1984: A Case Study from a Neuroblastoma Collection.","authors":"Laure Sanvee-Edoh, Kouamé Ambroise Kintossou, Séverine Tabone-Eglinger","doi":"10.1177/19475535261428051","DOIUrl":"https://doi.org/10.1177/19475535261428051","url":null,"abstract":"<p><strong>Introduction: </strong>The Biological Sample Management Platform (PGEB) of the Centre Léon Bérard is responsible for the preparation, preservation, storage, and provision of the institution's sample collection. The PGEB was approached to integrate a neuroblastoma collection, one of the most common pediatric cancers. This collection was initiated through the diagnostic reference activity for neuroblastoma at the Centre Léon Bérard.</p><p><strong>Objectives: </strong>To requalify pediatric biological samples collected between 1984 and 2024 and to make them available for pediatric research protocols.</p><p><strong>Methods: </strong>This study began with an assessment of the data associated with each of the 21,389 samples in the collection. These data were then compared with relevant regulations and consensus documents related to biobank data management, as well as the minimum data requirements for research use. Based on this, a methodology for sorting samples-either for retention or disposal-was applied.</p><p><strong>Results: </strong>A set of minimum information criteria was established to revalue the samples. Various texts applicable in France mention the minimum data required for making samples available, but no consensus exists, either nationally or internationally. Furthermore, 65% of the samples met the criteria and were retained for future research use.</p><p><strong>Conclusions: </strong>This article describes the research work that led to the identification of minimum required data. However, further development is needed to harmonize practices regarding data management and interoperability.</p>","PeriodicalId":55358,"journal":{"name":"Biopreservation and Biobanking","volume":" ","pages":"19475535261428051"},"PeriodicalIF":1.4,"publicationDate":"2026-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147391754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: ISO 20387:2018 is the first international standard specifically designed for biobanks, defining requirements for competence, impartiality, and operational consistency. In 2022, the Multi-Specialistic Biobank of the Azienda Ospedaliero-Universitaria Pisana became the first biobank in Italy to achieve ISO 20387 accreditation, setting a national benchmark for public-sector quality governance.
Approach: The accreditation pathway followed a structured 12-month plan combining gap analysis, document harmonization, competence development, and internal audits. A multidisciplinary quality working group redesigned the quality management system and aligned managerial and operational processes with ISO 20387 requirements. Fourteen quality documents were revised or newly developed to standardize workflows, strengthen traceability, and embed risk-based principles throughout the biobank's activities.
Outcomes: ISO 20387 accreditation was granted on July 14, 2022. Subsequent surveillance audits in 2023, 2024, and 2025 confirmed sustained compliance and progressive improvements, including expanded internal audits, enhanced risk assessment, digital competence tracking, and strengthened Corrective and Preventive Action effectiveness. Persistent challenges-including infrastructural constraints, limited information technology support, and delays in software modifications-reflected structural limitations typical of public health care settings.
Significance: This article provides an integrated account of ISO 20387 implementation and long-term maintenance in a public hospital biobank. The Pisa experience offers a replicable model for institutions operating under similar constraints, demonstrating how technical rigor, coordinated governance, and a shared quality culture can sustain accreditation and advance national biobanking excellence.
{"title":"Implementation and Long-Term Maintenance of ISO 20387:2018 in a Public Hospital Biobank: The Pisa Experience.","authors":"Alessandra Zucca, Elisa Biagi, Francesca Nocchi, Simone Lapi","doi":"10.1177/19475535261428401","DOIUrl":"https://doi.org/10.1177/19475535261428401","url":null,"abstract":"<p><strong>Background: </strong>ISO 20387:2018 is the first international standard specifically designed for biobanks, defining requirements for competence, impartiality, and operational consistency. In 2022, the Multi-Specialistic Biobank of the Azienda Ospedaliero-Universitaria Pisana became the first biobank in Italy to achieve ISO 20387 accreditation, setting a national benchmark for public-sector quality governance.</p><p><strong>Approach: </strong>The accreditation pathway followed a structured 12-month plan combining gap analysis, document harmonization, competence development, and internal audits. A multidisciplinary quality working group redesigned the quality management system and aligned managerial and operational processes with ISO 20387 requirements. Fourteen quality documents were revised or newly developed to standardize workflows, strengthen traceability, and embed risk-based principles throughout the biobank's activities.</p><p><strong>Outcomes: </strong>ISO 20387 accreditation was granted on July 14, 2022. Subsequent surveillance audits in 2023, 2024, and 2025 confirmed sustained compliance and progressive improvements, including expanded internal audits, enhanced risk assessment, digital competence tracking, and strengthened Corrective and Preventive Action effectiveness. Persistent challenges-including infrastructural constraints, limited information technology support, and delays in software modifications-reflected structural limitations typical of public health care settings.</p><p><strong>Significance: </strong>This article provides an integrated account of ISO 20387 implementation and long-term maintenance in a public hospital biobank. The Pisa experience offers a replicable model for institutions operating under similar constraints, demonstrating how technical rigor, coordinated governance, and a shared quality culture can sustain accreditation and advance national biobanking excellence.</p>","PeriodicalId":55358,"journal":{"name":"Biopreservation and Biobanking","volume":" ","pages":"19475535261428401"},"PeriodicalIF":1.4,"publicationDate":"2026-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147328239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-28DOI: 10.1177/19475535261422295
Rachel Hanisch, Lisa Gallicchio, Danielle Daee, Somdat Mahabir, Stefanie Nelson, Danielle M Carrick
Introduction: Biospecimens are an important part of conducting population-based research as they allow the linkage of biological information to other important clinical, social, and environmental factors, providing a more robust understanding of cancer prevention, treatment, and care options. It can be costly and labor-intensive to collect and process these biospecimens, making the use of preexisting, banked biospecimens an appealing option for researchers.
Objective: This study examines the use of existing biospecimens in National Cancer Institute (NCI)-funded population-based cancer control research grants managed by the Division of Cancer Control and Population Sciences (DCCPS) as of January 2024.
Methods: A total of 104 grants managed by DCCPS, NCI that involved the use of existing biospecimens were included in this analysis. Information that was abstracted from the grants included cancer type, biospecimen type, study design (intervention or observational), cancer continuum category (risk/etiology or survivorship), and named biospecimen resource.
Results: The most commonly used biospecimens were blood products (64.4%), DNA (59.6%), tissue (53.8%), and RNA (26.9%). Risk-focused studies mainly used blood products, while survivorship studies favored tissue and RNA. There was also a notable difference in biospecimen use between studies of common versus rare cancers, with rare cancer studies using tissue and RNA samples less frequently than studies of common cancers.
Conclusion: The variety of biospecimen types being used to examine a breadth of hypotheses related to cancer risk and survivorship emphasizes the value of biospecimen resources across the cancer continuum.
{"title":"Current Assessment of Existing Biospecimen Use in Population-Based Cancer Research.","authors":"Rachel Hanisch, Lisa Gallicchio, Danielle Daee, Somdat Mahabir, Stefanie Nelson, Danielle M Carrick","doi":"10.1177/19475535261422295","DOIUrl":"10.1177/19475535261422295","url":null,"abstract":"<p><strong>Introduction: </strong>Biospecimens are an important part of conducting population-based research as they allow the linkage of biological information to other important clinical, social, and environmental factors, providing a more robust understanding of cancer prevention, treatment, and care options. It can be costly and labor-intensive to collect and process these biospecimens, making the use of preexisting, banked biospecimens an appealing option for researchers.</p><p><strong>Objective: </strong>This study examines the use of existing biospecimens in National Cancer Institute (NCI)-funded population-based cancer control research grants managed by the Division of Cancer Control and Population Sciences (DCCPS) as of January 2024.</p><p><strong>Methods: </strong>A total of 104 grants managed by DCCPS, NCI that involved the use of existing biospecimens were included in this analysis. Information that was abstracted from the grants included cancer type, biospecimen type, study design (intervention or observational), cancer continuum category (risk/etiology or survivorship), and named biospecimen resource.</p><p><strong>Results: </strong>The most commonly used biospecimens were blood products (64.4%), DNA (59.6%), tissue (53.8%), and RNA (26.9%). Risk-focused studies mainly used blood products, while survivorship studies favored tissue and RNA. There was also a notable difference in biospecimen use between studies of common versus rare cancers, with rare cancer studies using tissue and RNA samples less frequently than studies of common cancers.</p><p><strong>Conclusion: </strong>The variety of biospecimen types being used to examine a breadth of hypotheses related to cancer risk and survivorship emphasizes the value of biospecimen resources across the cancer continuum.</p>","PeriodicalId":55358,"journal":{"name":"Biopreservation and Biobanking","volume":" ","pages":"19475535261422295"},"PeriodicalIF":1.4,"publicationDate":"2026-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12965398/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147319240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-27DOI: 10.1177/19475535251385419
Yanhong H Zhang, Jinxiu X Wang, Chunyu Y He, Qingyi Y Guo
Plant germplasm is critical for maintaining biodiversity and mitigating genetic erosion. While cryopreservation has emerged as an increasingly vital approach for conserving plant genetic resources, its routine application remains limited due to species- and explant-specific preservation requirements. In many instances, additional experimentation is necessary to develop genotype-specific protocols to achieve satisfactory survival rates. In addition, the technical operation is time-consuming and labor-intensive. Moreover, the survival rate of explants post-cryopreservation from many species remains suboptimal. PVS-based vitrification cryopreservation of dormant buds represents an ideal strategy to address these challenges, leveraging the buds' inherent cold hardiness and robust regrowth capacity. This review focuses on four key determinants of successful PVS-based cryopreservation: the collection time and physiological status of dormant buds, shoot tip dissection, PVS exposure duration, and recovery culture. The insights provided herein may facilitate the rapid development of new protocols or user-friendly procedures for a broader range of plant species, enabling wider adoption by institutions and laboratories, and thereby enhancing global efforts in germplasm conservation.
{"title":"Cryopreservation of Dormant Buds by PVS-Based Vitrification: A Highly Promising Strategy for Large-Scale Cryobanking of Plant Genetic Resources.","authors":"Yanhong H Zhang, Jinxiu X Wang, Chunyu Y He, Qingyi Y Guo","doi":"10.1177/19475535251385419","DOIUrl":"10.1177/19475535251385419","url":null,"abstract":"<p><p>Plant germplasm is critical for maintaining biodiversity and mitigating genetic erosion. While cryopreservation has emerged as an increasingly vital approach for conserving plant genetic resources, its routine application remains limited due to species- and explant-specific preservation requirements. In many instances, additional experimentation is necessary to develop genotype-specific protocols to achieve satisfactory survival rates. In addition, the technical operation is time-consuming and labor-intensive. Moreover, the survival rate of explants post-cryopreservation from many species remains suboptimal. PVS-based vitrification cryopreservation of dormant buds represents an ideal strategy to address these challenges, leveraging the buds' inherent cold hardiness and robust regrowth capacity. This review focuses on four key determinants of successful PVS-based cryopreservation: the collection time and physiological status of dormant buds, shoot tip dissection, PVS exposure duration, and recovery culture. The insights provided herein may facilitate the rapid development of new protocols or user-friendly procedures for a broader range of plant species, enabling wider adoption by institutions and laboratories, and thereby enhancing global efforts in germplasm conservation.</p>","PeriodicalId":55358,"journal":{"name":"Biopreservation and Biobanking","volume":" ","pages":"19475535251385419"},"PeriodicalIF":1.4,"publicationDate":"2026-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145294483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-19DOI: 10.1177/19475535251382352
Jennifer Rammon, Eric A Tolliver, Renee Storandt, Connie Sosnoff, Lanqing Wang, Jan Drobeniuc, Christine M Pfeiffer, Rosemary L Schleicher, Carissa D Powers, Ekaterina M Mineva, Geraldine M McQuillan
Introduction: The effect of prolonged storage (12-19 years) on selected laboratory test results is examined in the National Health and Nutrition Examination Survey biospecimen collection to determine whether biospecimens stored long term in vapor-phase liquid nitrogen provide valid results once remeasured.
Methods: Biospecimens were selected for remeasurement using systematic random sampling for five analytes: cotinine, methylmalonic acid (MMA), vitamin A, vitamin E, and hepatitis C virus RNA (HCV-RNA). Measurements from the original specimens in 1999-2000 or 2005-2006 are compared with 2018-2019 measurements from the same survey participants and specimens. For quantitative analytes, measurement accuracy is assessed using standard method comparison procedures, precision is evaluated by comparing to quality control standards, and reproducibility is estimated by treating data like an incurred sample reanalysis. Qualitative measures are analyzed using concordance measures and exact binomial tests.
Results: Observed proportional differences are 3%-12% for cotinine in people who do not smoke, 11% for cotinine in people who smoke, -8% to 1% for vitamin A, 8%-9% for vitamin E, and -6% to 8% for MMA. Precision estimates are within the standards established by quality control data and generally applicable quality goals. Differences between measurements are within 20% of the average value for at least 85% of all samples. For qualitative HCV-RNA and MMA results, we observe 99% concordance between measurements.
Conclusions: Multipronged analysis showed that most differences are within acceptable ranges based on standard laboratory criteria for assessing accuracy, precision, and reproducibility. Results suggest future measurements and subsequent statistical analyses of stored serum specimens should be valid.
{"title":"The Stability of Never-Thawed Serum Biospecimens Stored in Vapor-Phase Liquid Nitrogen: Select Analytes from the National Health and Nutrition Examination Survey, 1999-2000 and 2005-2006.","authors":"Jennifer Rammon, Eric A Tolliver, Renee Storandt, Connie Sosnoff, Lanqing Wang, Jan Drobeniuc, Christine M Pfeiffer, Rosemary L Schleicher, Carissa D Powers, Ekaterina M Mineva, Geraldine M McQuillan","doi":"10.1177/19475535251382352","DOIUrl":"10.1177/19475535251382352","url":null,"abstract":"<p><strong>Introduction: </strong>The effect of prolonged storage (12-19 years) on selected laboratory test results is examined in the National Health and Nutrition Examination Survey biospecimen collection to determine whether biospecimens stored long term in vapor-phase liquid nitrogen provide valid results once remeasured.</p><p><strong>Methods: </strong>Biospecimens were selected for remeasurement using systematic random sampling for five analytes: cotinine, methylmalonic acid (MMA), vitamin A, vitamin E, and hepatitis C virus RNA (HCV-RNA). Measurements from the original specimens in 1999-2000 or 2005-2006 are compared with 2018-2019 measurements from the same survey participants and specimens. For quantitative analytes, measurement accuracy is assessed using standard method comparison procedures, precision is evaluated by comparing to quality control standards, and reproducibility is estimated by treating data like an incurred sample reanalysis. Qualitative measures are analyzed using concordance measures and exact binomial tests.</p><p><strong>Results: </strong>Observed proportional differences are 3%-12% for cotinine in people who do not smoke, 11% for cotinine in people who smoke, -8% to 1% for vitamin A, 8%-9% for vitamin E, and -6% to 8% for MMA. Precision estimates are within the standards established by quality control data and generally applicable quality goals. Differences between measurements are within 20% of the average value for at least 85% of all samples. For qualitative HCV-RNA and MMA results, we observe 99% concordance between measurements.</p><p><strong>Conclusions: </strong>Multipronged analysis showed that most differences are within acceptable ranges based on standard laboratory criteria for assessing accuracy, precision, and reproducibility. Results suggest future measurements and subsequent statistical analyses of stored serum specimens should be valid.</p>","PeriodicalId":55358,"journal":{"name":"Biopreservation and Biobanking","volume":" ","pages":"19475535251382352"},"PeriodicalIF":1.4,"publicationDate":"2026-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145287889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-19DOI: 10.1177/19475535251378202
Jannes A W Jansen, Mariël A van den Brand, Femmie de Vegt, Dorine W Swinkels
Objectives: Biobanks are crucial for clinical biomarker research, but pre-analytical processing can impact sample suitability. Insufficient reporting of pre-analytical methods can lead to invalid conclusions.
Methods: This study evaluated the pre-analytical reporting quality in 294 clinical biomarker studies using biobank plasma and serum samples published from 2018 to 2023, based on the Sample PREanalytical Code and the Biospecimen Reporting for Improved Study Quality guidelines.
Results: The analysis revealed frequent incomplete reporting. Key underreported elements included fasting time (reported in 31% of articles), freeze-thaw cycles (22.8%), internal transport (8.5%), and centrifugation settings (20%-35%). Demographic data (96.9%), storage temperatures (81%), and blood tube additives (82.7%) were more consistently reported. No significant correlation was found between reporting quality and journal impact factor.
Conclusions: Our findings highlight the need for standardized pre-analytical reporting to improve research replicability and biomarker study quality.
{"title":"Reporting of Pre-Analytical Processes in Biobanked Biomaterials: A Missed Opportunity to Address the Replicability Crisis in Clinical Biomarker Research.","authors":"Jannes A W Jansen, Mariël A van den Brand, Femmie de Vegt, Dorine W Swinkels","doi":"10.1177/19475535251378202","DOIUrl":"10.1177/19475535251378202","url":null,"abstract":"<p><strong>Objectives: </strong>Biobanks are crucial for clinical biomarker research, but pre-analytical processing can impact sample suitability. Insufficient reporting of pre-analytical methods can lead to invalid conclusions.</p><p><strong>Methods: </strong>This study evaluated the pre-analytical reporting quality in 294 clinical biomarker studies using biobank plasma and serum samples published from 2018 to 2023, based on the Sample PREanalytical Code and the Biospecimen Reporting for Improved Study Quality guidelines.</p><p><strong>Results: </strong>The analysis revealed frequent incomplete reporting. Key underreported elements included fasting time (reported in 31% of articles), freeze-thaw cycles (22.8%), internal transport (8.5%), and centrifugation settings (20%-35%). Demographic data (96.9%), storage temperatures (81%), and blood tube additives (82.7%) were more consistently reported. No significant correlation was found between reporting quality and journal impact factor.</p><p><strong>Conclusions: </strong>Our findings highlight the need for standardized pre-analytical reporting to improve research replicability and biomarker study quality.</p>","PeriodicalId":55358,"journal":{"name":"Biopreservation and Biobanking","volume":" ","pages":"19475535251378202"},"PeriodicalIF":1.4,"publicationDate":"2026-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145187747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-19DOI: 10.1177/19475535251359868
Vahid Shokri-Asl, Rasa Khodavirdilou, Hamed Hajipour, Maryam Pashaiasl, Amir Fattahi
Sperm cryopreservation (SC) is an acceptable laboratory procedure for long-term storage of sperm. However, this procedure causes sperm damage. This review aimed to systematically investigate the effects of herbal-based antioxidants (HBAs) application on sperm parameters during SC. Following determination of the main keywords and searching strategy, various databases were searched systematically. Primary and secondary screenings were applied based on inclusion/exclusion criteria. Finally, 27 randomized controlled trial studies using 15 different HBAs and involving 567 normal and 130 abnormal semen samples were included for the meta-analysis. HBAs administration before or during the SC process improved total motility (mean difference [MD]: -6.31 [95% confidence interval [CI]: -10.27, -2.34], p < 0.05), viability (MD: -1.21 [95% CI: -1.52, -0.89], p < 0.001), morphology (MD: -1.72 [95% CI: -2.89, -0.54], p < 0.05), reactive oxygen species (H2O2) (MD: 7.58 [95% CI: 3.90, 11.26], p < 0.001), DNA integrity (MD: -13.21 [95% CI: -19.94, -6.49], p < 0.001), and sperm DNA fragmentation (SDF) (MD: 3.76 [95% CI: 2.38, 5.14], p < 0.001) after thawing in normal specimens. In abnormal semen samples, the HBAs improved viability (MD: -8.54 [95% CI: -11.18, -5.19], p < 0.001), progressive motility (MD: -4.55 [95% CI: -7.37, -1.73], p < 0.05) and ameliorated SDF (MD: 3.76 [95% CI: 1.74, 5.79], p < 0.001). Also, HBAs had no effects on total motility (MD: -0.08 [95% CI: -3.29, 3.14], p > 0.05), and morphology (MD: -0.31 [95% CI: -0.71, 0.09], p > 0.05). Application of HBAs in cryomedia before and during SC can improve sperm parameters (including viability, motility, and morphology), decrease oxidative stress and SDF levels.
精子冷冻保存(SC)是一种可接受的精子长期储存的实验室程序。然而,这个过程会导致精子受损。本文旨在系统探讨中药抗氧化剂(HBAs)的应用对SC过程中精子参数的影响。在确定主要关键词和检索策略的基础上,系统检索了各种数据库。根据纳入/排除标准进行初级和次级筛查。最后,使用15种不同HBAs的27项随机对照试验纳入meta分析,涉及557例正常和130例异常精液样本。在SC过程之前或期间给药HBAs改善了总运动能力(平均差[MD]: -6.31[95%可信区间[CI]: -10.27, -2.34], p < 0.05)、活力(MD: -1.21 [95% CI: -1.52, -0.89], p < 0.001)、形态学(MD: -1.72 [95% CI: -2.89, -0.54], p < 0.05)、活性氧(H2O2) (MD: 7.58 [95% CI: 3.90, 11.26], p < 0.001)、DNA完整性(MD: -13.21 [95% CI: -19.94, -6.49], p < 0.001)和精子DNA片段化(SDF) (MD: 3.76 [95% CI: -19.94, -6.49], p < 0.001)。(2.38, 5.14), p < 0.001)。在异常精液样本中,HBAs改善了活力(MD: -8.54 [95% CI: -11.18, -5.19], p < 0.001),进行性运动(MD: -4.55 [95% CI: -7.37, -1.73], p < 0.05)和改善了SDF (MD: 3.76 [95% CI: 1.74, 5.79], p < 0.001)。此外,HBAs对总运动(MD: -0.08 [95% CI: -3.29, 3.14], p > 0.05)和形态学(MD: -0.31 [95% CI: -0.71, 0.09], p > 0.05)没有影响。在SC前和SC过程中在低温培养基中应用HBAs可以改善精子参数(包括活力、活力和形态),降低氧化应激和SDF水平。
{"title":"Application of Herbal-Based Antioxidants in Human Sperm Cryopreservation: A Systematic Review and Meta-Analysis Study.","authors":"Vahid Shokri-Asl, Rasa Khodavirdilou, Hamed Hajipour, Maryam Pashaiasl, Amir Fattahi","doi":"10.1177/19475535251359868","DOIUrl":"10.1177/19475535251359868","url":null,"abstract":"<p><p>Sperm cryopreservation (SC) is an acceptable laboratory procedure for long-term storage of sperm. However, this procedure causes sperm damage. This review aimed to systematically investigate the effects of herbal-based antioxidants (HBAs) application on sperm parameters during SC. Following determination of the main keywords and searching strategy, various databases were searched systematically. Primary and secondary screenings were applied based on inclusion/exclusion criteria. Finally, 27 randomized controlled trial studies using 15 different HBAs and involving 567 normal and 130 abnormal semen samples were included for the meta-analysis. HBAs administration before or during the SC process improved total motility (mean difference [MD]: -6.31 [95% confidence interval [CI]: -10.27, -2.34], <i>p</i> < 0.05), viability (MD: -1.21 [95% CI: -1.52, -0.89], <i>p</i> < 0.001), morphology (MD: -1.72 [95% CI: -2.89, -0.54], <i>p</i> < 0.05), reactive oxygen species (H<sub>2</sub>O<sub>2</sub>) (MD: 7.58 [95% CI: 3.90, 11.26], <i>p</i> < 0.001), DNA integrity (MD: -13.21 [95% CI: -19.94, -6.49], <i>p</i> < 0.001), and sperm DNA fragmentation (SDF) (MD: 3.76 [95% CI: 2.38, 5.14], <i>p</i> < 0.001) after thawing in normal specimens. In abnormal semen samples, the HBAs improved viability (MD: -8.54 [95% CI: -11.18, -5.19], <i>p</i> < 0.001), progressive motility (MD: -4.55 [95% CI: -7.37, -1.73], <i>p</i> < 0.05) and ameliorated SDF (MD: 3.76 [95% CI: 1.74, 5.79], <i>p</i> < 0.001). Also, HBAs had no effects on total motility (MD: -0.08 [95% CI: -3.29, 3.14], <i>p</i> > 0.05), and morphology (MD: -0.31 [95% CI: -0.71, 0.09], <i>p</i> > 0.05). Application of HBAs in cryomedia before and during SC can improve sperm parameters (including viability, motility, and morphology), decrease oxidative stress and SDF levels.</p>","PeriodicalId":55358,"journal":{"name":"Biopreservation and Biobanking","volume":" ","pages":"19475535251359868"},"PeriodicalIF":1.4,"publicationDate":"2026-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144669042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-19DOI: 10.1177/19475535251359865
Elizabeth Sarah Mayne
Biorepositories in African populations are an important tool to ensure inclusive research to benefit African populations and the African diaspora. The establishment of biorepositories in Africa may, however, be impeded if culturally sensitive practices are not followed with respect to community engagement and informed consent. Communitarianism is a philosophical model which can be applied to African ethical processes. This model considers the individual within the broader context of the community and is compatible with cultural and religious practices in diverse African countries. This review considers the application of communitarianism to ethical and socially acceptable biorepository best practice on the African continent.
{"title":"Thinking Outside the Individual Box-A Communitarian Approach to Bioethics for Biorepositories.","authors":"Elizabeth Sarah Mayne","doi":"10.1177/19475535251359865","DOIUrl":"10.1177/19475535251359865","url":null,"abstract":"<p><p>Biorepositories in African populations are an important tool to ensure inclusive research to benefit African populations and the African diaspora. The establishment of biorepositories in Africa may, however, be impeded if culturally sensitive practices are not followed with respect to community engagement and informed consent. Communitarianism is a philosophical model which can be applied to African ethical processes. This model considers the individual within the broader context of the community and is compatible with cultural and religious practices in diverse African countries. This review considers the application of communitarianism to ethical and socially acceptable biorepository best practice on the African continent.</p>","PeriodicalId":55358,"journal":{"name":"Biopreservation and Biobanking","volume":" ","pages":"19475535251359865"},"PeriodicalIF":1.4,"publicationDate":"2026-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144638693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}